SEARCH

SEARCH BY CITATION

References

  • 1
    Gelfand JM, Weinstein R, Porter SB et al. Prevalence and treatment of psoriasis in the United Kingdom: a population-based study. Arch Dermatol 2005;141:15371541.
  • 2
    Braun-Falco O, Plewig G, Wolff HH et al. Dermatology, 2nd ed. Berlin: Springer, 2000:585.
  • 3
    Lomholt G. Psoriasis. Prevalence, spontaneous course, and genetics. A census study on the prevalence of skin diseases on the Faroe Islands. Copenhagen: G.E.C. Gad, 1963.
  • 4
    Williams H, Naldi L, Diepgen T. Epidemiology of skin disease in Europe. In: Fritsch P, ed. White book, dermatology in Europe. Bern: European Dermatology Forum, 2001:515.
  • 5
    Belazarian L. New insights and therapies for teenage psoriasis. Curr Opin Pediatr 2008;20:419424.
  • 6
    Benoit S, Hamm H. Psoriasis im Kindes- und JugendalterKlinik und Therapie. Der Hautarzt 2009;60:100108.
  • 7
    Boccardi D, Menni S, La Vecchia D et al. Overweight and childhood psoriasis. Br J Dermatol 2009;161:484486.
  • 8
    Farber EM, Nall L. Childhood psoriasis. Cutis 1999;64:309314.
  • 9
    Siddha SK, Burden AD. Recognition and treatment of psoriasis in children. Paediatr Child Health 2007;17:390394.
  • 10
    De Jager ME, Van de Kerkhof PC, De Jong EM et al. Epidemiology and prescribed treatments in childhood psoriasis: a survey among medical professionals. J Dermatolog Treat 2009;20:254258.
  • 11
    Augustin M, Glaeske G, Radtke MA et al. Epidemiology and comorbidity of psoriasis in children. Br J Dermatol 2010;162:633636.
  • 12
    Federal Statistical Office. Statutory Health Insurance: Members, Insured Persons. Table (ad-hoc). http://www.gbe-bund.de, Accessed July 5, 2013.
  • 13
    German Federal Health Insurance Authority (BVA; 2008). So funktioniert der neue Risikostrukturausgleich im Gesundheitsfonds. http://www.bundesversicherungsamt.de/cln_108/nn_1046668/DE/Risikostrukturausgleich/Wie_funktioniert_Morbi_RSA,templateId=raw,property=publicationFile.pdf/Wie_funktioniert_Morbi_RSA.pdf Accessed April 25, 2013.
  • 14
    Buchner F, Wasem J. Needs for further improvement: risk adjustment in the German health insurance system. Health Policy 2003;65:2135.
  • 15
    Schaefer I, Rustenbach SJ, Radtke M et al. Epidemiologie der Psoriasis in Deutschland—Auswertung von Sekundärdaten einer gesetzlichen Krankenversicherung. Das Gesundheitswesen 2011;73:308313.
  • 16
    Brauser D. Children with psoriasis at risk of developing psychiatric disorders. American Academy of Dermatology, 68th Annual Meeting, Miami, FL. Abstract P505. Presented March 8, 2010.
  • 17
    Farber EM, Nall ML. The natural history of psoriasis in 5,600 patients. Dermatologica 1974;148:118.
  • 18
    Kaempfe S, Schäfer I, Glaeske G et al. Prevalence and health care situation of the juvenile psoriasis in Germany—results from a secondary data analysis. Poster 181. Cologne: German Congress for Health Services Research, 2011.
  • 19
    Picardi A, Mazzotti E, Gaetano P et al. Stress, social support, emotional regulation, and exacerbation of diffuse plaque psoriasis. Psychosomatics 2005;46:556564.
  • 20
    Sticherling M, Minden K, Küster RM. Psoriasis und Psoriasisarthritis im Kindes- und Jugendalter. Z Rheumatol 2007;66:349354.
  • 21
    Augustin M, Reich K, Glaeske G et al. Co-morbidity and age-related prevalence of psoriasis: analysis of health insurance data in Germany. Acta Derm Venereol 2010;90:147151.
  • 22
    Matusiewicz D, Wasem J, Körber A et al. Psoriasis im Kindes- und Jugendalter—eine bundesweite Ärztebefragung zur Versorgungssituation in Deutschland. Der Hautarzt 2012;10:801807.